Latest News - Moderna
Top Corporates Hub
Moderna
Does Moderna Need to Start Making Money?
09.06.2026 11:31
Moderna Is Losing Billions. Here's Why That Might Be Exactly the Right Strategy.
Reported Earlier, Moderna And University Of Oxford Receive UK MHRA Authorization To Begin Phase 1/2 Study Of mRNA Cancer Vaccine For Lynch Syndrome
09.06.2026 04:09
Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk of up to 80%[1]The INTERCEPT-Lynch trial is part of a scientific collaboration between the University of Oxford and
Ultragenyx (RARE) Down 13.6% Since Last Earnings Report: Can It Rebound?
04.06.2026 15:30
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Moderna (MRNA) Climbs 7.5% Ahead of Next Week’s Key Updates
04.06.2026 02:47
Moderna Inc. (NASDAQ:MRNA) is one of the 10 Stocks With Remarkable Resilience. Moderna snapped a four-day losing streak on Wednesday, jumping 7.49 percent to finish at $49.06 apiece, as investors positioned portfolios ahead of its participation in a conference next week. In a notice to investors, Moderna Inc. (NASDAQ:MRNA) said that it is set to […]
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
01.06.2026 12:00
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of ...
Moderna Joins Global Initiative to Advance Vaccine Candidate for Bundibugyo Ebola Virus (MRNA)
01.06.2026 10:38
Moderna (NASDAQ:MRNA) announced on Monday a new collaboration with an international health organization aimed at accelerating the development of a vaccine targeting Bundibugyo ebolavirus (BDBV), the strain responsible for the ongoing Ebola outbreak in eastern Democratic Republic of Congo. The partnership comes as global health agencies intensify efforts to identify effective treatments and preventive measures for the outbreak, which has resulted in more than 900 suspected infections and over 220
Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
01.06.2026 09:00
Coalition for Epidemic Preparedness Innovations funding builds on Moderna's prior filovirus research and supports preclinical development and Phase 1 clinical evaluation CAMBRIDGE, MA / ACCESS Newswire / June 1, 2026 / Moderna, Inc. (NASDAQ:MRNA) ...
Moderna, Inc. (MRNA) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
30.05.2026 03:54
Moderna, Inc. (MRNA) Bernstein 42nd Annual Strategic Decisions Conference May 28, 2026 10:00 AM EDTCompany ParticipantsStéphane Bancel - CEO &...
This Biotech Stock Is Stuck in the Red. Its Cancer Portfolio Is About to Change the Narrative.
27.05.2026 15:07
BioNTech’s future rests entirely on the success of its pipeline, now that its pandemic-era glory days are firmly in the rearview mirror. Wall Street is betting the company’s next act in oncology will be worth the wait. UBS analyst David Dai moved off the sidelines Wednesday as he upgraded BioNTech stock to Buy from Neutral with a $135 price target, up from $117.
Healthy Returns: Eli Lilly makes a new push into vaccines – here’s what to know
27.05.2026 10:57
The drugmaker announced it will buy three privately held vaccine makers in deals worth almost $4 billion combined.
Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine
26.05.2026 10:16
The Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new clearance in breast cancer and the FDA approved a drug for hepatitis D.
3 Cash-Burning Stocks with Open Questions
23.05.2026 09:56
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even bankruptcy.
MRNA Stock Slips: FDA Slates Advisory Hearing On Experimental Flu Shot
21.05.2026 16:45
The Food and Drug Administration is eyeing a meeting on June 18 to discuss mRNA-1010.
How The Roivant Sciences (ROIV) Story Is Shifting After Settlements And Brepocitinib Milestones
20.05.2026 03:13
Roivant Sciences has seen only a marginal shift in its modeled fair value, from US$35.67 to US$35.71, keeping the headline price target effectively stable. That small move reflects a tug of war in analyst commentary, with optimism around the US$2.25b Genevant and Arbutus settlement and key brepocitinib milestones set against questions about how much of this is already in the stock. Read on to see how to track these shifting views and what to watch as the Roivant story continues to...
What's going on in today's session: S&P500 gap up and gap down stocks
19.05.2026 14:35
Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Tuesday to uncover the stocks that are gapping in the S&P500 index.
Moderna, Inc. (MRNA) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
19.05.2026 12:20
Moderna, Inc. (MRNA) RBC Capital Markets Global Healthcare Conference 2026 May 19, 2026 10:00 AM EDTCompany ParticipantsLavina Talukdar - Senior VP &...
Cramer’s Stop Trading: Zoom Communications
19.05.2026 10:01
CNBC’s Jim Cramer explains why he is keeping an eye on shares of Zoom Communications.
25. Lila Sciences
19.05.2026 05:50
Lila Sciences, a "superintelligence platform" with a focus on scientific advances, ranks No. 25 on CNBC’s 2026 Disruptor 50 list.
Assessing Moderna (MRNA) Valuation After Flu Vaccine Trial Success And Hantavirus Research Attention
16.05.2026 16:13
Moderna (MRNA) is back in focus after Phase 3 data showed its mRNA flu vaccine outperformed standard shots in older adults, while separate hantavirus research tied to a cruise ship outbreak added further attention. See our latest analysis for Moderna. The latest flu and hantavirus updates come after a powerful run, with the stock showing a 58.91% year-to-date share price return and a very large 1-year total shareholder return. However, longer-term total shareholder returns over 3 and 5 years...
Hantavirus: Is there a risk of another pandemic?
16.05.2026 04:25
Investing.com -- Moderna Inc (NASDAQ:MRNA) shares rallied 13% over a multi-day period following reports of a localized Hantavirus outbreak aboard the cruise vessel MV Hondius.